摘要
目的 :观察FHP方案在中晚期原发性肝癌介入化疗栓塞治疗中应用的疗效及毒副反应。方法 :对 80例肝癌患者进行肝动脉化疗栓塞术。化疗药物分别选择 5 氟脲嘧啶或氟苷、羟基喜树碱和顺铂 (FHP组 ) 4 0例 ;5 氟脲嘧啶或氟苷、表阿霉素和丝裂霉素C(FAM组 ) 4 0例。观察疗效及血液、肝脏和心脏毒性反应。结果 :FHP组有效率为 5 7 5 0 % (2 3/ 4 0 ) ,FAM组为 35 0 0 % (14 / 10 ) ,组间比较差异有显著性 (P <0 0 5 )。FHP组患者白细胞Ⅲ Ⅳ级毒性反应的绝对值明显低于FAM组 ,但统计学分析无显著性差异 (P >0 0 5 ) ,其他如血小板、血红蛋白、转氨酶、胆红素等Ⅲ～Ⅳ级毒性反应比较无显著性差异 (P >0 0 5 )。FAM组LVEF发生轻度减退者 7例 (17 5 0 % ) ,严重减退 1例 (2 5 0 % ) ,而FHP组中无LVEF减退发生。组间比较差异有显著性 (P <0 0 5 )。结论 :FHP方案用于中晚期肝癌介入治疗具有较高的疗效 ,毒副反应发生率低。
Objective:To observe the efficacy and toxicity of FHP regimen in interventional chemoembolization of moderate and advanced stage of hepatocellular carcinoma.Methods:80 patients were treated with hepatic artery chemoembolization, they were divided into two groups. 40 cases were treated with 5-Fu/FuDR, HCPT and cisplatin(FHP),and 40 cases with 5-Fu/FuDR, EADM and MMC (FAM), The efficacy and hemotological toxicity, hepatoxicity and cardiotoxicity were observed.Results:The overall response rate in FHP group was 57.50%(23/40), and 35.00%(14/40) in FAM group, the difference between two groups was significant (P<0.05). White cell Ⅲ～Ⅳ toxicity in FHP group was obviously lower than that in FAM group, but there was not significant difference (P>0.05), The Ⅲ～Ⅳ grade of platelet, hemoglobin transaminase and bilirubin of toxicity were not different between two groups. In FAM group, there were 7 cases whose LVEF decreased slightly(17.50%), 1 cases whose LVEF decreased seriously (2.5%). in FHP group, there was not patients whose LVEF decreased, the difference between two groups was significant (P<0.05).Conclusion:FHP in interventional chemobolization is an efficient method with feaer side effects in the treatment of moderate and advanced stage of hepatocellular carcinoma.
出处
《临床肿瘤学杂志》
CAS
2004年第3期235-236,240,共3页
Chinese Clinical Oncology
